

Supplementary Material

Real-world tildrakizumab effectiveness and drug survival: a cohort study in the PPD

CorEvitas Psoriasis Registry

Jerry Bagel, MD;¹ Ranga Gogineni, PhD;² Asif Shaikh, MD, DrPH;² Taylor Blachley, MS;³

Thomas Eckmann, MPH;³ Alicia Beeghly, MPH, PhD;³ Mark G Lebwohl, MD⁴

¹Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA

²Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA

³Thermo Fisher Scientific, Waltham, MA, USA

⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Corresponding author: Jerry Bagel, MD, Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA; email: dreamacres1@aol.com

Figure S1. Study population




Table S1. Description of measures

Sociodemographic, Lifestyle, Comorbidity, Psoriasis, and Medication Measures	
Sociodemographic characteristics	• Age (years) • Sex (female, male) • Race (white, Black, other) • Ethnicity (Hispanic/Latino or non-Hispanic/Latino) • Health insurance plan type (private only, Medicare only, Medicaid only, Private plus Medicare, no insurance) • Education (no college or any college) • Work Status (full-time, part-time, student, disabled, retired, not working for pay)
Lifestyle characteristics	• Smoking status (never, former, current) • Current alcohol use (none, <1 drink per week, 1-3 drinks per week, 4-6 drinks per week, 1-2 drinks per day, >2 drinks per day) • Body height and weight • Body-mass index (BMI continuous and categorized using the CDC cut-offs for normal/underweight (under 25); Overweight (25.0 – 29.9); and Obese (30.0 and above))
History of comorbidities	• Psoriatic arthritis • Cancer • Infection (any infection, serious infection) • Cardiovascular disease (congestive heart failure, myocardial infarction, unstable angina, coronary artery disease, acute coronary syndrome, other cardiovascular disease) • Cerebrovascular disease (stroke/transient ischemic attack, peripheral arterial disease) • Hypertension • Hyperlipidemia • Diabetes • Metabolic syndrome • Peptic ulcer • Crohn's disease • Ulcerative colitis • Indeterminate inflammatory bowel disease and other gastrointestinal disorders • Depression • Anxiety • Number of comorbidities
Psoriasis disease characteristics	• Age at onset • Age at diagnosis • Duration of disease • Difficult to treat areas • Psoriasis morphologies • Psoriasis Epidemiology Screening Tool (PEST) score • Duration of psoriatic arthritis (if applicable) <i>Note: PEST is in the public domain</i>
Medications	• Prior therapies ○ Number of prior biologic therapies ○ Type of prior biologic therapy (TNFi, IL-17i, IL-12/23i, IL-23i) ○ Number of prior non-biologic systemic therapies ○ Type of non-biologic systemic therapies (acitretin, cyclosporine, methotrexate (MTX), apremilast, deucravacitinib)

	- Concomitant therapies - Non-biologic systemic therapies (acitretin, cyclosporine, methotrexate (MTX), apremilast, deucravacitinib)
Disease Activity Measures (Range)	
Psoriasis Area and Severity Index (PASI)	Description: - A composite score assessing disease severity and coverage developed for clinical research - Includes an assessment of body surface area (BSA) Components: PASI consists of 2 components: - Area Affected: assessed for 4 regions of the body - Head/neck (10% total BSA) - Upper extremities (20% total BSA) - Torso (30% total BSA) - Lower extremities (40% total BSA) - Severity: Lesions in each area are assessed for severity of 3 characteristics on a scale of 0 (none) to 4 (very severe) - Erythema (redness) - Induration (thickness) - Scaling Formula: - The sum of all three severity parameters is calculated for each region of the body, multiplied by the area score for that area and multiplied by weight of respective section (0.1 for head, 0.2 for arms, 0.3 for body and 0.4 for legs) and totaled Range: - Total PASI score ranges from 0 to 72 where 0 (no psoriasis) and 72 (the most severe psoriasis) Direction: - Higher PASI score indicates more severe disease Categories: - Mild: $0 \leq \text{PASI} \leq 5$ - Moderate: $5 < \text{PASI} \leq 12$ - Severe: $12 < \text{PASI} \leq 20$ - Very Severe: $20 < \text{PASI} \leq 72$ Response: - PASI75: At least 75% improvement (reduction) from baseline to follow-up - PASI90: At least 90% improvement (reduction) from baseline to follow-up - PASI100: Indicates resolution of all disease from baseline to follow-up <i>Note: PASI is in the public domain</i>
% Body Surface Area (BSA) (0 to 100%)	Description: - Current percent involvement of the patient's body that is affected by psoriasis - Score is a percentage where 1 patient handprint = 1% total BSA (includes palm, fingers and thumb) - Assessed for 4 regions of the body: - Head/neck - Upper extremities - Torso - Lower extremities Range:

	- The BSA score is a percentage ranging from 0% to 100% Direction: - Higher BSA score indicates more severe disease Categories: - Mild: BSA < 3% - Moderate: 3% ≤ BSA ≤ 10% - Severe: BSA > 10% Response: - BSA<1: Achieving BSA <1 - BSA<3: Achieving BSA < 3 - BSA75: At least 75% improvement (reduction) from baseline to follow-up <i>Note: BSA is in the public domain</i>
Investigator's Global Assessment (IGA)	Description: - Physician reported degree of redness, scaling and thickness of psoriasis lesions Range: 0-4 where 0 (clear) & 4 (severe disease) Direction: - Higher IGA score indicates more severe disease Categories: 0= Clear (No signs of psoriasis, post inflammatory hyperpigmentation may be present) 1= Almost clear (No thickening; normal to pink coloration; no to minimal focal scaling) 2= Mild Disease (Just detectable to mild thickening; pink to light red coloration; predominantly fine scaling) 3= Moderate Disease (Clearly distinguishable to moderate thickening; dull to bright red; moderate scaling) 4= Severe Disease (Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions) Response: - IGA 0/1: Proportion achieving of IGA 0 (clear) or 1 (almost clear) among those with baseline IGA>1 <i>Note: IGA is used with permission from Novartis</i>
Patient-Reported Outcomes Measures (Range)	
Patient Global Assessment (PGA)	Description: Patient reported assessment of disease severity Values 0 (clear) to 4 (severe) Values/Components: 0 = Clear, 1 = Almost Clear, 2 = Mild, 3 = Moderate, 4 = Severe Direction: Higher value indicates worse condition <i>Note: PGA is in the public domain</i>
Dermatology Life Quality Index (DLQI, 0 to 30)	Description: Patient's perception of the impact of skin problems on different aspects of their health-related quality of life in the past week 10 questions in 6 subscale scores

	• Symptoms and feelings • Daily activities • Leisure • Work or school • Personal relationships • Side effects of treatments Total score: 0 - 30 where 0 (best) and 30 (worst) Categories: 0-1: No effect at all on patient's life 2-5: Small effect on patient's life 6-10: Moderate effect on patient's life 11-20: Very large effect on patient's life 21-30: Extremely large effect on patient's life Direction: Higher score indicates greater the impact on quality of life <i>Note: DLQI was used with permission. © Dermatology Life Quality Index. A Y Finlay, G K Khan, April 1992</i>
Patient Skin Pain Assessment (0 to 10)	Description: A patient-reported pain measure on a 0-10 visual analog scale (VAS) where patients are asked to rate their worst skin pain over the past 24 hours (0=no pain; 10=worst imaginable pain) Range: 0-10 VAS where 0=no pain and 10=worst imaginable pain Direction: Higher score indicates more severe pain <i>Note: the skin pain VAS is in the public domain</i>
Patient Fatigue Assessment (0 to 10)	Description: A patient-reported fatigue measure on a 0-10 VAS where patients are asked to rate their worst level of fatigue (weariness, tiredness) in the past 7 days (0=no fatigue; 10=worst imaginable fatigue) Range: 0-10 VAS where 0=no fatigue and 10=worst imaginable fatigue Direction: Higher score indicates higher fatigue <i>Note: the fatigue VAS is in the public domain</i>
Peak Pruritus (itch, 0-10)	Description: A patient-reported itch measure on a 0-10 VAS where patients are asked to rate their worst itch in the past 24 hours (0=no itch; 10=worst imaginable itch) Range: 0-10 VAS where 0=no itch and 10=worst imaginable itch Direction: Higher score indicates more severe itch <i>Note: the itch VAS is in the public domain</i>
Euro-Quality of Life (QoL) 5-Dimension 3 Level (EQ-5D-3L)	Description: • A standardized measure of health-related quality of life comprised of 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression • Each dimension has 3 levels: ○ no problems (0)

	○ some problems (1) ○ extreme problems (2) Range: • 0 to 2 Interpretation: • Higher scores indicate poorer health <i>Note: the EQ-5D-3L is used with permission. © The Medical Outcomes Trust (MOT), Health Assessment Lab (HAL) and QualityMetric Incorporated</i>
EQ Health Status	Description: • A patient-reported health measure on a vertical 0-100 visual analog scale (VAS) where patients are asked to rate how good or bad their health is today (0=worst imaginable health; 100=best imaginable health) Range: • 0-100 VAS Direction: • Higher score indicates better health <i>Note: the EQ is used with permission. © The Medical Outcomes Trust (MOT), Health Assessment Lab (HAL) and QualityMetric Incorporated</i>
Work Productivity and Activity Impairment (WPAI, 0 to 100%)	Description: Respondents are asked questions concerning impairment due to psoriasis Questions: 1 = Currently employed? 2 = Hours missed due to psoriasis? 3 = Hours missed other reasons? 4 = Hours actually worked? 5 = Degree problem affected productivity while working (0 to 10 numeric rating scale [NRS])? 6 = Degree problem affected regular activities (0-10 NRS)? Scores: Multiply scores by 100 to express in percentages: • Absenteeism (work time missed): $Q2/(Q2+Q4)$ • Presenteeism (impairment while working): $Q5/10$ • Work productivity loss (overall work impairment): $Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4)))(Q5/10)]$ • Activity impairment: $Q6/10$ Range: Current employment: yes/no 0 - 100% Direction: High numbers indicate greater impairment and less productivity <i>Note: the WPAI is in the public domain</i>

Table S2. All baseline patient characteristics for tildrakizumab initiators in the PPD CorEvitas Psoriasis Registry, overall and by biologic experience

	Total N = 728	Biologic Naïve N = 345	Biologic Experienced N = 383	Standardized Differences ^a
<i>Demographics/socioeconomic characteristics</i>				
Age (years), mean (SD)	58.4 (15.8)	57.5 (16.6)	59.2 (15.1)	0.105
Sex (Female), n (%)	347 (47.7%)	157 (45.5%)	190 (49.6%)	0.041
Race, n (%)				
White	592 (81.3%)	271 (78.6%)	321 (83.8%)	0.072
Black/African American	30 (4.1%)	18 (5.2%)	12 (3.1%)	
Other	106 (14.6%)	56 (16.2%)	50 (13.1%)	
Ethnicity (Hispanic), n (%)	61 (8.6%)	32 (9.5%)	29 (7.8%)	0.032
Health insurance, n (%)				
Private Only	270 (42.1%)	125 (43.6%)	145 (41.0%)	0.079
Medicare Only	263 (41.0%)	110 (38.3%)	153 (43.2%)	
Private + Medicare	41 (6.4%)	16 (5.6%)	25 (7.1%)	
Medicaid	62 (9.7%)	33 (11.5%)	29 (8.2%)	
No Insurance	5 (0.8%)	3 (1.0%)	2 (0.6%)	
Education (Any College), n (%)	299 (41.2%)	152 (44.4%)	147 (38.4%)	0.061
Work status, n (%)				
Full-time	307 (42.3%)	164 (47.8%)	143 (37.4%)	0.147
Part-time	47 (6.5%)	16 (4.7%)	31 (8.1%)	
Not working for pay	49 (6.8%)	19 (5.5%)	30 (7.9%)	
Student	4 (0.6%)	4 (1.2%)	0 (0.0%)	
Disabled	48 (6.6%)	19 (5.5%)	29 (7.6%)	
Retired	270 (37.2%)	121 (35.3%)	149 (39.0%)	
<i>Lifestyle characteristics</i>				
Smoking history, n (%)				
Never smoked	325 (45.6%)	158 (47.2%)	167 (44.3%)	0.033
Former smoker	267 (37.5%)	124 (37.0%)	143 (37.9%)	
Current smoker	120 (16.9%)	53 (15.8%)	67 (17.8%)	
Current alcohol use, n (%)				
None	253 (36.8%)	116 (35.9%)	137 (37.6%)	0.055
< 1 drink per week	151 (22.0%)	68 (21.1%)	83 (22.8%)	
1-3 drinks per week	111 (16.2%)	50 (15.5%)	61 (16.8%)	
4-6 drinks per week	60 (8.7%)	31 (9.6%)	29 (8.0%)	
1-2 drinks per day	60 (8.7%)	31 (9.6%)	29 (8.0%)	
> 2 drinks per day	52 (7.6%)	27 (8.4%)	25 (6.9%)	
Body height (cm), mean (SD)	169.8 (11.1)	169.5 (11.8)	170.0 (10.5)	0.050
Body weight (kg), mean (SD)	88.4 (23.0)	86.4 (22.3)	90.2 (23.5)	0.167
BMI (kg/m ²), mean (SD)	30.6 (7.3)	30.1 (7.4)	31.0 (7.1)	0.118

BMI (kg/m ²) category, n (%) ^b				
BMI < 25 (Underweight/normal)	143 (21.2%)	88 (26.7%)	55 (15.9%)	0.133
BMI 25 - < 30 (Overweight)	215 (31.8%)	98 (29.8%)	117 (33.7%)	
BMI ≥ 30 (Obese)	318 (47.0%)	143 (43.5%)	175 (50.4%)	
<i>History of comorbidities, n (%)</i>				
Cancer ^c	73 (10.1%)	35 (10.2%)	38 (9.9%)	0.004
Infection ^d	268 (36.8%)	94 (27.2%)	174 (45.4%)	0.188
- Serious infection	41 (5.6%)	13 (3.8%)	28 (7.3%)	0.077
Cardio/cerebrovascular disease ^e	99 (13.6%)	49 (14.2%)	50 (13.1%)	0.017
- Cardiovascular disease	99 (13.6%)	49 (14.2%)	50 (13.1%)	0.017
-- Congestive heart failure	11 (1.5%)	3 (0.9%)	8 (2.1%)	0.050
-- Myocardial infarction	17 (2.3%)	9 (2.6%)	8 (2.1%)	0.017
-- Unstable angina	5 (0.7%)	1 (0.3%)	4 (1.0%)	0.046
-- Coronary artery disease	23 (3.2%)	11 (3.2%)	12 (3.1%)	0.002
-- Acute coronary syndrome	1 (0.1%)	1 (0.3%)	0 (0.0%)	0.039
-- Other CVD	53 (7.3%)	28 (8.1%)	25 (6.5%)	0.031
- Cerebrovascular disease	14 (1.9%)	3 (0.9%)	11 (2.9%)	0.073
-- Stroke/Transient ischemic attack	12 (1.6%)	3 (0.9%)	9 (2.3%)	0.058
-- Peripheral arterial disease	2 (0.3%)	0 (0.0%)	2 (0.5%)	0.050
Hypertension	307 (42.3%)	142 (41.3%)	165 (43.2%)	0.019
Hyperlipidemia	236 (32.5%)	102 (29.7%)	134 (35.1%)	0.058
Diabetes	131 (18.0%)	56 (16.3%)	75 (19.6%)	0.044
Metabolic syndrome	3 (0.4%)	0 (0.0%)	3 (0.8%)	0.061
Peptic Ulcer	5 (0.7%)	3 (0.9%)	2 (0.5%)	0.021
Crohn's Disease	4 (0.6%)	2 (0.6%)	2 (0.5%)	0.004
Ulcerative Colitis	7 (1.0%)	5 (1.5%)	2 (0.5%)	0.048
Indeterminate IBD and other GI disorders	57 (7.8%)	12 (3.5%)	45 (11.7%)	0.154
Depression	120 (16.5%)	51 (14.8%)	69 (18.1%)	0.044
Anxiety	137 (18.9%)	58 (16.9%)	79 (20.7%)	0.049
Number of comorbidities, n (%) ^f				
0	498 (68.6%)	243 (70.6%)	255 (66.8%)	0.042
1	181 (24.9%)	80 (23.3%)	101 (26.4%)	
2 +	47 (6.5%)	21 (6.1%)	26 (6.8%)	
<i>Disease characteristics</i>				
Psoriasis morphology, n (%)				
Guttate	44 (6.0%)	27 (7.8%)	17 (4.4%)	0.071
Erythrodermic	28 (3.8%)	10 (2.9%)	18 (4.7%)	0.047
Pustular (localized)	7 (1.0%)	5 (1.4%)	2 (0.5%)	0.047
Pustular (generalized)	3 (0.4%)	0 (0.0%)	3 (0.8%)	0.061
Inverse/intertriginous	70 (9.6%)	29 (8.4%)	41 (10.7%)	0.039
Psoriasis location, n (%)				
Scalp	290 (39.8%)	133 (38.6%)	157 (41.0%)	0.025
Nail	78 (10.7%)	29 (8.4%)	49 (12.8%)	0.071

Palmoplantar	64 (8.8%)	22 (6.4%)	42 (11.0%)	0.081
Genital	61 (8.4%)	26 (7.5%)	35 (9.1%)	0.029
Age at psoriasis symptom onset (years), mean (SD)	39.4 (19.8)	42.5 (20.6)	36.6 (18.7)	0.305
Age at psoriasis diagnosis (years), mean (SD)	42.0 (19.5)	45.4 (20.0)	39.0 (18.6)	0.329
PsO duration (years), mean (SD)	16.3 (16.1)	12.2 (15.2)	20.0 (16.1)	0.497
PsO disease duration category, n (%)				
0 - < 5 years	223 (30.8%)	155 (45.1%)	68 (17.9%)	0.311
5 - < 10 years	113 (15.6%)	55 (16.0%)	58 (15.3%)	
10 - < 15 years	75 (10.4%)	29 (8.4%)	46 (12.1%)	
15 - < 20 years	62 (8.6%)	22 (6.4%)	40 (10.6%)	
≥ 20 years	250 (34.6%)	83 (24.1%)	167 (44.1%)	
Psoriatic Arthritis (PsA), n (%)	223 (31.0%)	55 (16.1%)	168 (44.4%)	0.306
PsA duration (years) among subjects with PsA, mean (SD)	9.5 (10.6)	5.7 (9.4)	10.8 (10.8)	0.484
PEST, n (%)				
0	240 (33.6%)	144 (42.2%)	96 (25.7%)	0.248
1	156 (21.8%)	79 (23.2%)	77 (20.6%)	
2	144 (20.1%)	69 (20.2%)	75 (20.1%)	
3	87 (12.2%)	26 (7.6%)	61 (16.3%)	
4	55 (7.7%)	17 (5.0%)	38 (10.2%)	
5	33 (4.6%)	6 (1.8%)	27 (7.2%)	
PEST 3+, n (%)	175 (24.5%)	49 (14.4%)	126 (33.7%)	0.224
<i>Disease activity</i>				
BSA (%), mean (SD)	13.6 (15.3)	16.0 (15.0)	11.5 (15.3)	0.300
BSA category, n (%)				
Mild disease [0,3)	135 (18.5%)	31 (9.0%)	104 (27.2%)	0.265
Moderate disease [3,10)	305 (41.9%)	141 (40.9%)	164 (42.8%)	
Severe disease [10,100]	288 (39.6%)	173 (50.1%)	115 (30.0%)	
PASI (0 - 72), mean (SD)	7.7 (7.3)	9.6 (7.7)	5.9 (6.3)	0.535
PASI > 10, n (%)	221 (30.4%)	137 (39.7%)	84 (22.0%)	0.192
Investigator Global Assessment, mean (SD)	2.6 (1.0)	2.9 (0.8)	2.3 (1.2)	0.594
IGA category, n (%)				
0: Clear	52 (7.1%)	5 (1.4%)	47 (12.3%)	0.298
1: Almost clear	52 (7.1%)	10 (2.9%)	42 (11.0%)	
2: Mild	156 (21.4%)	65 (18.8%)	91 (23.8%)	
3: Moderate	367 (50.4%)	206 (59.7%)	161 (42.0%)	
4: Severe	101 (13.9%)	59 (17.1%)	42 (11.0%)	
<i>Treatment characteristics</i>				
Concomitant therapy, n (%)				
With systemic therapy	71 (9.8%)	39 (11.3%)	32 (8.4%)	0.050
With topical agents	346 (47.5%)	211 (61.2%)	135 (35.2%)	0.259
With phototherapy	29 (4.0%)	21 (6.1%)	8 (2.1%)	0.102

Biologic experience, n (%) ^g				
0 previous biologic agents	345 (47.4%)	345 (100.0%)	0 (0.0%)	-----
1 previous biologic agent	158 (21.7%)	0 (0.0%)	158 (41.3%)	
2 previous biologic agents	104 (14.3%)	0 (0.0%)	104 (27.2%)	
3+ previous biologic agents	121 (16.6%)	0 (0.0%)	121 (31.6%)	
Prior biologic class, n (%)				
TNFi	80 (15.0%)	0 (0.0%)	80 (21.0%)	-----
IL-12/23i	62 (11.6%)	0 (0.0%)	62 (16.3%)	
IL-23i	77 (14.4%)	0 (0.0%)	77 (20.2%)	
IL-17i	115 (21.6%)	0 (0.0%)	115 (30.2%)	
Non-biologic experience, n (%) ^h				
0 previous non-biologic agents	356 (48.9%)	193 (55.9%)	163 (42.6%)	0.207
1 previous non-biologic agent	274 (37.6%)	130 (37.7%)	144 (37.6%)	
2+ previous non-biologic agents	98 (13.5%)	22 (6.4%)	76 (19.8%)	
Overall itch/pruritus (VAS range 0-100)	727	345	382	
Mean (SD)	46.0 (34.4)	51.5 (32.8)	41.1 (35.2)	0.305
Median (Q1, Q3)	50.0 (10.0, 77.0)	55.0 (20.0, 80.0)	35.0 (5.0, 75.0)	
Overall fatigue (VAS range 0-100)	724	343	381	
Mean (SD)	32.3 (29.4)	32.1 (28.6)	32.4 (30.1)	0.009
Median (Q1, Q3)	25.0 (5.0, 53.5)	25.0 (5.0, 52.0)	25.0 (4.0, 55.0)	
Overall skin pain (VAS range 0-100)	725	344	381	
Mean (SD)	29.7 (32.5)	33.4 (33.3)	26.3 (31.4)	0.221
Median (Q1, Q3)	15.0 (0.0, 56.0)	20.0 (2.0, 63.5)	10.0 (0.0, 50.0)	
Patient global assessment (VAS range 0-100)	726	343	383	
Mean (SD)	46.1 (30.7)	51.7 (29.5)	41.2 (30.9)	0.348
Median (Q1, Q3)	50.0 (17.0, 75.0)	50.0 (25.0, 80.0)	40.0 (10.0, 70.0)	
WPAI summary scores ⁱ				
Currently employed, n (%)	351 (48.2%)	178 (51.6%)	173 (45.2%)	0.064
Absenteeism	320	162	158	
Mean (SD)	4.2 (16.0)	3.5 (13.9)	4.8 (17.9)	0.079
Presenteeism	316	161	155	
Mean (SD)	12.4 (20.5)	15.0 (22.8)	9.7 (17.5)	0.263
Work productivity loss	314	160	154	
Mean (SD)	13.6 (21.6)	15.6 (23.2)	11.5 (19.6)	0.191
Activity impairment	711	337	374	
Mean (SD)	20.1 (27.1)	21.6 (27.8)	18.8 (26.4)	0.101
Percent of work hours missed due to psoriasis	345	176	169	
Mean (SD)	1.5 (6.6)	1.4 (5.9)	1.5 (7.3)	0.002
Median (Q1, Q3)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	
Percent of impairment while working due to psoriasis	316	161	155	
Mean (SD)	12.4 (20.5)	15.0 (22.8)	9.7 (17.5)	0.263

Median (Q1, Q3)	3.0 (0.0, 15.2)	5.0 (0.0, 20.0)	1.0 (0.0, 10.0)	
Overall % of work hours affected by psoriasis	340	173	167	
Mean (SD)	36.1 (16.8)	36.3 (16.4)	35.8 (17.3)	0.030
Median (Q1, Q3)	40.0 (30.0, 45.0)	40.0 (35.0, 45.0)	40.0 (28.2, 41.0)	
Percent of daily activities impacted by psoriasis	711	337	374	
Mean (SD)	20.1 (27.1)	21.6 (27.8)	18.8 (26.4)	0.101
Median (Q1, Q3)	5.0 (0.0, 30.0)	10.0 (0.0, 35.0)	5.0 (0.0, 30.0)	
DLQI (0 - 30)	722	342	380	
Mean (SD)	7.3 (6.2)	8.2 (5.9)	6.4 (6.4)	0.282
Median (Q1, Q3)	6.0 (2.0, 11.0)	7.0 (3.0, 12.0)	4.0 (1.0, 9.2)	
DLQI Effect on life, n (%)				0.242
0-1: None	140 (19.4%)	34 (9.9%)	106 (27.9%)	
2-5: Small	214 (29.6%)	105 (30.7%)	109 (28.7%)	
6-10: Moderate	168 (23.3%)	91 (26.6%)	77 (20.3%)	
11-20: Very large	169 (23.4%)	99 (28.9%)	70 (18.4%)	
21-30: Extremely large	31 (4.3%)	13 (3.8%)	18 (4.7%)	
Patient health state today (VAS range 0-100)	720	342	378	
Mean (SD)	72.4 (19.0)	72.0 (18.7)	72.7 (19.4)	0.039
Median (Q1, Q3)	78.0 (60.0, 88.0)	75.0 (60.0, 85.0)	80.0 (60.0, 90.0)	
EQ-5D-3L categorical domains, n (%) ⁱ				
Walking	214 (29.5%)	89 (25.8%)	125 (32.9%)	0.078
Self-care	68 (9.4%)	30 (8.7%)	38 (10.0%)	0.022
Usual activities	197 (27.1%)	86 (24.9%)	111 (29.1%)	0.047
Pain/discomfort	415 (57.1%)	189 (54.8%)	226 (59.2%)	0.044
Anxiety/depression	235 (32.4%)	108 (31.4%)	127 (33.2%)	0.020
Problems with sleeping, n (%)	121 (16.8%)	69 (20.3%)	52 (13.7%)	0.088

^a Standardized differences calculated as Cohen's w or Cohen's d statistics for categorical or continuous characteristics, respectively.

^b Based on the CDC cut-offs for normal/underweight (under 25); Overweight (25.0 – 29.9); and Obese (30.0 and above).

^c Cancer includes lymphoma, lung, breast, skin [melanoma], and any other cancers.

^d Infections include joint/bursa, cellulitis/skin, sinusitis, candida, diverticulitis, sepsis, pneumonia, bronchitis, gastroenteritis, meningitis/encephalitis, urinary tract, upper respiratory, TB, and other. Infections resulting in hospitalization or administration of IV antibiotics indicated as a serious infection.

^e Cardio/cerebrovascular disease includes a baseline history of any of the following: cardiac revascularization procedure, ventricular arrhythmia, cardiac arrest, myocardial infarction, acute coronary syndrome, unstable angina, coronary artery disease, and congestive heart failure; cerebrovascular disease includes baseline history of any of the following: stroke, TIA, peripheral vascular disease, and peripheral arterial disease.

^f The number of comorbidities is a sum of the following physician reported comorbidities: myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease (stroke or transient ischemic attack), chronic obstructive pulmonary disease, peptic ulcer, diabetes mellitus, lymphoma, cancer, and liver disease.

^g Prior biologic use does not include subject's current biologic, if applicable.

^h Prior non-biologic systemic use does not include subject's current non-biologic systemic therapy, if applicable.

ⁱ Absenteeism, presenteeism, and work productivity loss are only among employed patients.

^j Reported as n (%) with moderate/severe impairment for each domain.

Abbreviations: BMI, body mass index; BSA, body surface area; CVD, cardiovascular disease; DLQI, Dermatology Life Quality Index; EQ-5D-3L, Euro-Quality of Life 5 Dimension 3 Level; GI, gastrointestinal; IBD, inflammatory bowel disease; IGA, Investigator's Global Assessment; PASI, Psoriasis Area and Severity Index; PEST, Psoriasis Epidemiology Screening Tool; PsO, psoriasis; SD, standard deviation; VAS, visual analog scale; WPAI, Work Productivity and Activity Impairment.

Figure S2. Kaplan-Meier plot for time to discontinuation of tildrakizumab among initiators with at least one follow-up visit in the PPD CorEvitas Psoriasis Registry, overall




Figure S3. Kaplan-Meier plot for time to discontinuation of tildrakizumab among initiators with at least one follow-up visit in the PPD CorEvitas Psoriasis Registry, by biologic experience

